GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NovelStem International Corp (OTCPK:NSTM) » Definitions » Gross Profit

NovelStem International (NovelStem International) Gross Profit : $0.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is NovelStem International Gross Profit?

NovelStem International's gross profit for the three months ended in Dec. 2023 was $0.00 Mil. NovelStem International's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. NovelStem International's gross profit for the three months ended in Dec. 2023 was $0.00 Mil. NovelStem International's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, NovelStem International's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

NovelStem International had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of NovelStem International was 25.12%. The lowest was 20.65%. And the median was 24.63%.


NovelStem International Gross Profit Historical Data

The historical data trend for NovelStem International's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovelStem International Gross Profit Chart

NovelStem International Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.07 0.62 - 0.01 0.01

NovelStem International Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - 0.01 -

Competitive Comparison of NovelStem International's Gross Profit

For the Diagnostics & Research subindustry, NovelStem International's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovelStem International's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's Gross Profit distribution charts can be found below:

* The bar in red indicates where NovelStem International's Gross Profit falls into.



NovelStem International Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

NovelStem International's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.012 - 0
=0.01

NovelStem International's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.003 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

NovelStem International's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0.003
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


NovelStem International  (OTCPK:NSTM) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

NovelStem International had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


NovelStem International Gross Profit Related Terms

Thank you for viewing the detailed overview of NovelStem International's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


NovelStem International (NovelStem International) Business Description

Traded in Other Exchanges
N/A
Address
2255 Glades Road, Suite 221A, Boca Raton, FL, USA, 33431
NovelStem International Corp owns novel stem-cell-based diagnostic technology for predicting patients' resistance to cancer therapies. The technology is also being used for genetic research related to other medical therapies.
Executives
Baker Street Capital Management, Llc 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Vadim Perelman 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Baker Street Capital L.p. 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Stephen Gans director, 10 percent owner 14850 NW 44TH COURT, OPA LOCKA FL 33054
Shannon River Partners Lp 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Fund Management Co Llc 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Partners Ii, Lp 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Doonbeg Fund Lp 10 percent owner 850 THIRD AVE, 13TH FLOOR, New York ny 10022
Spencer M. Waxman director C/O SHANNON RIVER PARTNERS, 800 THIRD AVENUE 30TH FLOOR, NEW YORK NY 10022
Stanley Morgan 10 percent owner 1585 BROADWAY, NEW YORK NY 10036
Robert D. Epstein director 2255 GLADES ROAD, BOCA RATON FL 33431
Coghill Capital Management Llc 10 percent owner 233 SOUTH WACKER DRIVE, SUITE 8439, CHICAGO IL 60606
Ccm Master Fund Ltd 10 percent owner C/O MORGAN STANLEY FUND SERVICES (CAYMAN, LTD CENTURY YARD CRICKET SQ HUTCHINGS DR, PO BOX 2681 GEORGE TOWN E9 00000
Clint D Coghill 10 percent owner
Scott Gomez officer: Chief Accounting Officer

NovelStem International (NovelStem International) Headlines

From GuruFocus

NewStem Announces $4 million Seed Investment

By PRNewswire PRNewswire 07-16-2018